m****g
发帖数: 530 | 1 PR Newswire US - Jul. 29, 2009
SEATTLE, July 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. announced
today that it was notified by
the European Medicines Agency that pixantrone is eligible to be submitted
for a MAA through the EMEA's
centralized procedure. CTI completed the submission of the NDA to the FDA
for pixantrone to treat relapsed
or refractory, aggressive NHL in June 2009 and requested priority review,
which if granted could lead to an
approval decision from the FDA in the fourth |
|
